The global demand for tetracyclines remains strong, driven by their broad-spectrum efficacy and cost-effectiveness in ...

Aurobindo Pharma Ltd (BOM:524804) reports robust revenue growth driven by European operations and US injectable sales, while addressing regulatory challenges and strategic acquisitions.

The FTSE 100 traded sideways and US indices and European stocks were mixed on Monday, as the market looks ahead to this ...